The pATM Immunofluorescence assay: a high-performance radiosensitivity assay to predict post radiotherapy overreactions. - Archive ouverte HAL Access content directly
Journal Articles International Journal of Radiation Oncology, Biology, Physics Year : 2018

The pATM Immunofluorescence assay: a high-performance radiosensitivity assay to predict post radiotherapy overreactions.

Abstract

Purpose dentifying prior treatment, the patients who will overreact to radiotherapy (RT) would have sound positive clinical implications. By focusing on DNA double-strand breaks (DSB) recognition and repair proteins after irradiation, we recently demonstrated that the maximal number of pATM nuclear foci in the first hour (pATMmax) after ex vivo irradiation correlated with post-RT toxicity severity. We aimed to carry out additional analyses on our whole collection of fibroblast lines to refine the predictive performance of our assay.
Fichier principal
Vignette du fichier
Rouge_2018.pdf (131.08 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01757771 , version 1 (03-04-2018)

Identifiers

Cite

Guillaume Vogin, Thierry Bastogne, Larry Bodgi, Julien Gillet-Daubin, Aurélien Canet, et al.. The pATM Immunofluorescence assay: a high-performance radiosensitivity assay to predict post radiotherapy overreactions.. International Journal of Radiation Oncology, Biology, Physics, 2018, 101 (3), pp.690-693. ⟨10.1016/j.ijrobp.2018.03.047⟩. ⟨hal-01757771⟩
393 View
544 Download

Altmetric

Share

Gmail Facebook X LinkedIn More